HC Wainwright Has Optimistic Outlook of PTGX Q1 Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Investment analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for shares of Protagonist Therapeutics in a research report issued to clients and investors on Thursday, February 26th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.70) for the quarter, up from their previous estimate of ($0.71). HC Wainwright currently has a “Buy” rating and a $117.00 price target on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q2 2026 earnings at $1.98 EPS, Q3 2026 earnings at $3.60 EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at $4.18 EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($2.08) EPS, FY2029 earnings at $0.12 EPS and FY2030 earnings at $1.22 EPS.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). The company had revenue of $7.44 million during the quarter, compared to analysts’ expectations of $14.92 million. Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.

Several other equities research analysts also recently issued reports on the stock. Citizens Jmp lifted their price target on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Truist Financial lifted their target price on Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. TD Cowen boosted their price target on Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Jefferies Financial Group raised their price objective on Protagonist Therapeutics from $95.00 to $118.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Finally, Citigroup lifted their price objective on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $99.31.

Protagonist Therapeutics Trading Up 2.3%

NASDAQ PTGX opened at $94.24 on Monday. The stock has a market cap of $6.01 billion, a P/E ratio of -45.97 and a beta of 2.23. The company’s fifty day simple moving average is $84.38 and its 200-day simple moving average is $77.44. Protagonist Therapeutics has a 52 week low of $37.20 and a 52 week high of $96.54.

Institutional Investors Weigh In On Protagonist Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Farallon Capital Management LLC boosted its stake in Protagonist Therapeutics by 0.4% in the third quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock valued at $411,601,000 after acquiring an additional 24,000 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Protagonist Therapeutics by 27.2% in the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock worth $472,832,000 after purchasing an additional 1,156,461 shares during the last quarter. BVF Inc. IL lifted its holdings in shares of Protagonist Therapeutics by 24.7% in the 2nd quarter. BVF Inc. IL now owns 3,211,041 shares of the company’s stock worth $177,474,000 after purchasing an additional 636,026 shares during the last quarter. State Street Corp boosted its position in Protagonist Therapeutics by 18.5% during the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock valued at $177,281,000 after purchasing an additional 500,924 shares during the period. Finally, Wellington Management Group LLP grew its stake in Protagonist Therapeutics by 66.2% during the 4th quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock worth $276,992,000 after buying an additional 1,262,977 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insiders Place Their Bets

In related news, Director Lewis T. Williams sold 18,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $82.42, for a total transaction of $1,483,560.00. Following the sale, the director directly owned 7,825 shares of the company’s stock, valued at approximately $644,936.50. This represents a 69.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 4,068 shares of Protagonist Therapeutics stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $83.19, for a total transaction of $338,416.92. Following the completion of the transaction, the chief executive officer directly owned 574,505 shares of the company’s stock, valued at approximately $47,793,070.95. This represents a 0.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 203,167 shares of company stock worth $16,889,199. Corporate insiders own 4.90% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.